Deep Genomics develops an AI platform for RNA biology to identify novel targets and evaluate therapeutic candidates for genetic conditions.

Deep Genomics

BASE mRNA facility focuses on messenger RNA design, manufacturing, and research. They provide end-to-end research services to design, manufacture, and test new mRNA medicines.

BASE mRNA facility

Beverly Hills Institute of Ophthalmology provides ophthalmology services including LASIK surgery, cataract surgery, and comprehensive eye care. The institute is described as having advanced technology and a team of experienced ophthalmologists.

Beverly Hills Institute of Ophthalmology

AI in Pharma: Discovery is focused on exploring the applications of AI-based technology in drug discovery and development, specifically how AI, ML, NLP, data science, and generative deep learning models can optimize the pharmaceutical and biotechnology industries.

AI in Pharma: Discovery

MaRS Discovery District

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.

The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

True Ventures

Khosla Ventures

Silicon Valley Ventures

Magnetic Ventures

Amplitude Venture Capital

NJF Capital

Future Ventures

Alexandria Venture Investments

SoftBank Vision Fund

CPP Investments

Fidelity Management and Research Company

It was great to bring the full Deep Genomics team together in Toronto this past week — and you can see some of what we got up to in the photos below!

Our days were spent in live brainstorms with our teams, taking updated headshots, and spending focused time with our leaders to strengthen the support for our employees and culture; all before we took the chance to wind down and socialise (and play some video games too - make sure you scroll to the last photo…)

We’re continuing to grow this incredible team. It’s important that as we grow, so do the connections between us all. That’s why we’re hosting these events quarterly, giving us as much “face time” as possible and bringing us closer together!

Interested in joining the Deep Genomics team? Check out the current openings within the Toronto and Boston teams, and learn how you can help make a difference: https://lnkd.in/gPbZ_jpF.

#deepgenomics #techbio #toronto #pharmaindustry #teambuilding

We had a great day celebrating National Intern Day yesterday (July 25) in our office!

We put together a special lunch and some goodies to show appreciation to all our interns here at Deep Genomics. And, of course, there had to be some (competitive!) table tennis going on.

Have a look at some of the highlights in our gallery below.

#internappreciation #nationalinternday #deepgenomics

Continuing our Deep Genomics team spotlights, we’re excited to share a look at our incredible VP and Head of Target Identification, Tehmina Masud!

Tehmina’s achievements know no bounds. A Fulbright scholar, she has studied and trained in Pakistan, Canada, and the United States. With 10+ research papers published on genome biology and targeted therapies, we’re thrilled to have Tehmina on our team.

You can find out more about Tehmina in the graphics below.

#deepgenomics #techbio #teamspotlight #toronto #boston

We are thrilled to share new photos of our Toronto and Cambridge offices!

In case you missed our latest news, Deep Genomics recently celebrated the opening of our new office and lab facility in Cambridge, Massachusetts, and expanded our existing Toronto facility.

As our Chief Scientific Officer Greg Hoffman puts it, it’s an exciting time for our company. “The Cambridge office expansion and lab opening will be a huge asset for fostering collaboration between teams, combining wet lab and machine learning expertise, to usher in a new era of pharma R&D.”

See pictures from both locations below. You can learn more about our expansion, including new hires, at https://lnkd.in/eFWrcCGM.

Interested in joining the Deep Genomics team? Check out the current openings within the teams in our two offices and learn how you can help make a difference: https://lnkd.in/gPbZ_jpF.

#deepgenomics #techbio #expansion #massachusetts #toronto #pharmaindustry

We're #hiring a new Senior Machine Learning Operations Engineer (ML Ops) - Accelerating Drug Discovery with AI in Toronto, Ontario. Apply today or share this post with your network.

We're #hiring a new Senior Machine Learning Scientist (ML) - Accelerating Drug Discovery with AI in Toronto, Ontario. Apply today or share this post with your network.

Metric
Company Name	Deep Genomics	BASE mRNA facility	Beverly Hills Institute of Ophthalmology	AI in Pharma: Discovery
Symbol
MSH ID	COM:DEEPGENOMICS	AU:ORG:BASEFACILITY	COM:90210EYES	COM:AIINPHARMA-DISCOVERY
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Medical Services	Pharmaceuticals
Country	CA	AU	US	US
Stage
Employee Count	107
Website	deepgenomics.com	basefacility.org.au	90210eyes.com	aiinpharma-discovery.com
LinkedIn	deep-genomics	base-facility
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:DEEPGENOMICS

Deep Genomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue